Anavex Appoints Senior Healthcare and Pharmaceutical Executives to Board of Directors

Anavex Encouraged by Scientific Data Confirming Sigma-1 Receptor Agonist is Potentially Disease-Modifying in Parkinson’s Disease

Anavex Strengthens Alzheimer’s Pipeline, Obtains Exclusive Worldwide Rights to Intellectual Property

Anavex Reports Predicted Clinical Effect of Both ANAVEX 2-73 and ANAVEX PLUS in a Humanized Cortical Cognitive Model for Alzheimer’s Disease

Anavex Successfully Closes $10 Million Financing to Initiate Phase 1b/2a Alzheimer’s Clinical Trial

Anavex Announces $10 Million Private Placement of Convertible Debentures

Anavex Encouraged By Scientific Data Confirming Sigma-1 Receptor Agonist Extends Survival in ALS (Lou Gehrig’s Disease)

Anavex: Research Report Reveals Cardioprotective Action of Sigma-1 Receptor Agonists

Research Report Confirms Opportunity for Anavex Anti-Cancer and Neuropathic Pain Compounds